Search

A correction is presented to the article "Invertebrate biodiversity continues to decline in cropland" published in a previous issue of the periodical.

Although humans have long been predators with enduring nutritive and cultural relationships with their prey, seldom have conservation ecologists considered the divergent predatory behavior of contemporary, industrialized humans. Recognizing that the number, strength and diversity of predator-prey relationships can profoundly influence biodiversity, here we analyze humanity's modern day predatory interactions with vertebrates and estimate their ecological consequences. Analysing IUCN 'use and trade' data for ~47,000 species, we show that fishers, hunters and other animal collectors prey on more than a third (~15,000 species) of Earth's vertebrates. Assessed over equivalent ranges, humans exploit up to 300 times more species than comparable non-human predators. Exploitation for the pet trade, medicine, and other uses now affects almost as many species as those targeted for food consumption, and almost 40% of exploited species are threatened by human use. Trait space analyses show that birds and mammals threatened by exploitation occupy a disproportionally large and unique region of ecological trait space, now at risk of loss. These patterns suggest far more species are subject to human-imposed ecological (e.g., landscapes of fear) and evolutionary (e.g., harvest selection) processes than previously considered. Moreover, continued overexploitation will likely bear profound consequences for biodiversity and ecosystem function. Predatory niche and ecological trait space analyses identify modern humans as unique predators of vertebrates. [ABSTRACT FROM AUTHOR]

Modern agriculture has drastically changed global landscapes and introduced pressures on wildlife populations. Policy and management of agricultural systems has changed over the last 30 years, a period characterized not only by intensive agricultural practices but also by an increasing push towards sustainability. It is crucial that we understand the long-term consequences of agriculture on beneficial invertebrates and assess if policy and management approaches recently introduced are supporting their recovery. In this study, we use large citizen science datasets to derive trends in invertebrate occupancy in Great Britain between 1990 and 2019. We compare these trends between regions of no- (0%), low- (greater than 0–50%) and high-cropland (greater than 50%) cover, which includes arable and horticultural crops. Although we detect general declines, invertebrate groups are declining most strongly in high-cropland cover regions. This suggests that even in the light of improved policy and management over the last 30 years, the way we are managing cropland is failing to conserve and restore invertebrate communities. New policy-based drivers and incentives are required to support the resilience and sustainability of agricultural ecosystems. Post-Brexit changes in UK agricultural policy and reforms under the Environment Act offer opportunities to improve agricultural landscapes for the benefit of biodiversity and society. [ABSTRACT FROM AUTHOR]

Biodiversity targets are a key tool, used at a global and national policy level, to align biodiversity goals, promote conservation action, and recover nature. Yet most biodiversity targets are not met. In England, the government has committed to legally‐binding targets to halt and recover the decline in species abundance by 2030 and 2042. We present evidence from recent population trends of 670 terrestrial animal species (for which abundance time series are available) as a species abundance indicator, together with a synthesis of case studies on species recovery, to assess the degree to which these targets are achievable. The case studies demonstrate that recovery is possible through a range of approaches. The indicator demonstrates that theoretically targets can be achieved by addressing severe declines in a relatively small number of species, as well as creating smaller benefits for many species through landscape‐scale interventions. The fact that multiple pathways exist to achieve the species abundance targets in England presents choices but also raises the possibility that targets might be reached with perverse consequences. We demonstrate that evidence on achievability is a necessary but not sufficient condition for determining what is required to deliver conservation outcomes and restore biodiversity. [ABSTRACT FROM AUTHOR]

Protected areas are a key conservation tool, yet their effectiveness at maintaining biodiversity through time is rarely quantified. Here, we assess protected area effectiveness across sampled portions of Great Britain (primarily England) using regionalized (protected vs unprotected areas) Bayesian occupancy-detection models for 1238 invertebrate species at 1 km resolution, based on ~1 million occurrence records between 1990 and 2018. We quantified species richness, species trends, and compositional change (temporal beta diversity; decomposed into losses and gains). We report results overall, for two functional groups (pollinators and predators), and for rare and common species. Whilst we found that protected areas have 15 % more species on average than unprotected ones, declines in occupancy are of similar magnitude and species composition has changed 27 % across protected and unprotected areas, with losses dominating gains. Pollinators have suffered particularly severe declines. Still, protected areas are colonized by more locally-novel pollinator species than unprotected areas, suggesting that they might act as 'landing pads' for range-shifting pollinators. We find almost double the number of rare species in protected areas (although rare species trends are similar in protected and unprotected areas); whereas we uncover disproportionately steep declines for common species within protected areas. Our results highlight strong invertebrate reorganization and loss across both protected and unprotected areas. We therefore call for more effective protected areas, in combination with wider action, to bend the curve of biodiversity loss – where we provide a toolkit to quantify effectiveness. We must grasp the opportunity to effectively conserve biodiversity through time. [ABSTRACT FROM AUTHOR]

In an attempt to better constrain the timing of Variscan HP-HT metamorphism in the SE Bohemian Massif we have dated zoned zircons from a garnet-kyanite granulite of granitic composition from the Dunkelsteiner Wald Massif, Lower Austria, by means of sensitive high-resolution ion microprobe (SHRIMP) technique. In order to combine isotopic information with crystal growth textures, CL and BSE images were systematically taken from the dated zircons. A characteristic threefold concentric zoning was found in many zircons. This involves pre-Variscan protolithic cores followed by two distinct metamorphic/anatectic overgrowth shells of Variscan age. The inner overgrowth shell is characterized by a weak CL but bright BSE signal, and yields high contents of uranium (0.1 to 0.2 wt.%). A pooled U-Pb Concordia age for this zone is 342.0 ± 3.0 Ma ( n = 11, MSWD = 0.12). The second, outer, overgrowth shell is always bright in the CL image, dark in the BSE image, and has generally low uranium contents (mostly <500 ppm). A pooled U-Pb Concordia age for this zone is 337.1 ± 2.7 Ma ( n = 11, MSWD = 0.22). These results imply that the Variscan HT crystallisation history of the Moldanubian granulites took place over a period of a few million years and was not an extremely rapid subduction-exhumation process. SHRIMP measurements in the protolithic cores yield a cluster of (sub)concordant ages between ∼390 and 460 Ma and a few outliers at higher ages mostly represented by cores in cores. Core domains, which are large, homogeneous and with undisturbed igneous oscillatory zoning, yielded preferentially ages between 430 and 460 Ma. We therefore consider that granitic protolith formation took place at that time. The still older inner cores are interpreted as inherited into the granitic melt. [ABSTRACT FROM AUTHOR]

The impact of structural biology on drug discovery is well documented, and the workhorse technique for the past 30 years or so has been X-ray crystallography. With the advent of several technological improvements, including direct electron detectors, automation, better microscope vacuums and lenses, phase plates and improvements in computing power enabled by GPUs, it is now possible to record and analyse images of protein structures containing high-resolution information. This review, from a pharmaceutical perspective, highlights some of the most relevant and interesting protein structures for the pharmaceutical industry and shows examples of how ligand-binding sites, membrane proteins, both big and small, pseudo symmetry and complexes are being addressed by this technique. [ABSTRACT FROM AUTHOR]

Protease-activated receptor-2 (PAR2) has been implicated in multiple pathophysiologies but drug discovery is challenging due to low small molecule tractability and a complex activation mechanism. Here we report the pharmacological profiling of a potent new agonist, suggested by molecular modelling to bind in the putative orthosteric site, and two novel PAR2 antagonists with distinctly different mechanisms of inhibition. We identify coupling between different PAR2 binding sites. One antagonist is a competitive inhibitor that binds to the orthosteric site, while a second antagonist is a negative allosteric modulator that binds at a remote site. The allosteric modulator shows probe dependence, more effectively inhibiting peptide than protease activation of PAR2 signalling. Importantly, both antagonists are active in vivo, inhibiting PAR2 agonist-induced acute paw inflammation in rats and preventing activation of mast cells and neutrophils. These results highlight two distinct mechanisms of inhibition that potentially could be targeted for future development of drugs that modulate PAR2. Kennedy et al. report the pharmacological and in vivo profiling of two small molecule PAR2 inhibitors and an agonist. They conclude that while the small molecule agonist and one of the inhibitors bind to the orthosteric PAR2 binding site, the other inhibitor is a negative allosteric modulator, highlighting two distinct mechanisms of inhibition that could be targeted for future development of drugs that modulate PAR2. [ABSTRACT FROM AUTHOR]